Inclusion Criteria:

- Patient (e) Age (e) over 18 years

- Kidney cancer metastatic or locally advanced

- Anti-angiogenic or targeted therapy (bevacizumab, sorafenib, sunitinib, temsirolimus,
another molecule or developing or having obtained authorization in this indication)
may be associated with interferon or combined together

- Proposed treatment in first line or second line

- Brain imaging not finding brain metastases

- Having signed the informed consent of study participation

- The patient may have received prior anti-angiogenic

Exclusion Criteria:

- Cancer of the kidney other than primitive

- Previous history of cancer other than kidney cancer in complete remission for less
than 5 years

- Patients under 18 years

- Patients whose treatment is associated with chemotherapy

- disorders of cognitive functions to existing treatment delivery

- Pathology psychiatric evolutionary

- Refusal of participation

- Patient unable to respond to cognitive tests

- Drug use

- Heavy drinking (WHO criteria)

- History of stroke

- History of head trauma

- Brain metastases known

- MMS below normal compared to existing standards for age and socio-cultural